Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.
Saved in:
| Title: | Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial. |
|---|---|
| Authors: | Werner B; Gynaecological Cancer Research Group, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia., Sjoquist KM; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia., Espinoza D; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia., Yip S; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia., Chang G; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia., Cummins MM; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia., Mileshkin L; Peter MacCallum Cancer Centre, Melbourne, Australia., Ananda S; Peter MacCallum Cancer Centre, Melbourne, Australia; Western Health, Furlong Road, St Albans, Australia; Epworth Freemasons Hospital, East Melbourne, Australia; Department of Medicine, Western Health, University of Melbourne, Melbourne, Australia., Shannon C; Mater Cancer Care Centre, South Brisbane, Australia., Friedlander M; Prince of Wales Hospital, Sydney, Australia; School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia., Warton K; Gynaecological Cancer Research Group, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia., Ford CE; Gynaecological Cancer Research Group, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia. Electronic address: caroline.ford@unsw.edu.au. |
| Source: | Translational oncology [Transl Oncol] 2024 May; Vol. 43, pp. 101914. Date of Electronic Publication: 2024 Feb 27. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Neoplasia Press Country of Publication: United States NLM ID: 101472619 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1936-5233 (Print) Linking ISSN: 19365233 NLM ISO Abbreviation: Transl Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
